-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Saturday, Nurix Advances Bexobrutideg NX-5948 Into Global DAYBreak-CLL-201 Phase 2 Enrollment Following Phase 1 Durability And Tolerability Data

Benzinga·12/08/2025 09:13:15
Listen to the news
  • Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested
  • Emerging data from randomized Phase 1b cohorts points to higher ORR and longer progression free survival at the 600 mg recommended Phase 2 dose (RP2D) compared to the 200 mg dose
  • Bexobrutideg was well tolerated with a consistent safety profile between the 600 mg RP2D and the overall study population
  • Phase 2 clinical trial of bexobrutideg (DAYBreak-CLL-201) currently enrolling globally